The FDA has expanded the approval of Farxiga (dapagliflozin) to include treatment of heart failure patients regardless of left ventricular ejection fraction status.
AstraZeneca s heart failure treatment approved for expanded use in US pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
The FDA has expanded the approval of Farxiga (dapagliflozin) to include treatment of heart failure patients regardless of left ventricular ejection fraction status.
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER .